Traitements actuels du lymphome folliculaire [Current treatment of follicular lymphoma]

Détails

ID Serval
serval:BIB_FD7BC57F2F1D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Traitements actuels du lymphome folliculaire [Current treatment of follicular lymphoma]
Périodique
Revue Médicale Suisse
Auteur(s)
Bonnet C., Beguin Y., Deprijck B., de Leval L., Fillet G.
ISSN
1660-9379[print], 1660-9379[linking]
Statut éditorial
Publié
Date de publication
2009
Volume
5
Numéro
214
Pages
1663-1667
Langue
français
Résumé
After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is now reserved for young patients in first relapse. Allogenic stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade).
Mots-clé
Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Boronic Acids/administration & dosage, Chemotherapy, Adjuvant, Cyclophosphamide/administration & dosage, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Follicular/drug therapy, Lymphoma, Follicular/radiotherapy, Prednisone/administration & dosage, Prognosis, Pyrazines/administration & dosage, Radioimmunotherapy, Radiotherapy, Adjuvant, Risk Factors, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Vincristine/administration & dosage
Pubmed
Création de la notice
22/10/2010 13:33
Dernière modification de la notice
20/08/2019 16:28
Données d'usage